Glaxo Smith Kline results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements.
Net profit13.81 millionEGP · −98.4% vs the same period a year earlier
Total assets3.12 billionEGP · −10.5% vs the same period a year earlier
Shareholders' equity1.96 billionEGP · −12.0% vs the same period a year earlier
Operating cash flow-290 millionEGP · −147.2% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Q1 2023 was about 13.81 million EGP, down −98.4% from 869 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 3.12 billion EGP, and shareholders' equity about 1.96 billion EGP.
- Operating cash flow for Q1 2023 was negative at 290 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit13.81 million869 million−98.4%
Gross profit119 million113 million+5.4%
Total assets3.12 billion3.49 billion−10.5%
Total liabilities1.16 billion1.26 billion−7.9%
Shareholders' equity1.96 billion2.23 billion−12.0%
Total liabilities and equity3.12 billion3.49 billion−10.5%
Operating cash flow-290 million-117 million−147.2%
Investing cash flow-7.05 million-7.32 million+3.8%
Financing cash flow-42.37 million-127 million+66.7%
Net change in cash-339 million-252 million−34.8%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy